# Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation

> **NCT04366232** · PHASE2 · TERMINATED · sponsor: **Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer** · enrollment: 2 (actual)

## Conditions studied

- Covid-19

## Interventions

- **DRUG:** Anakinra alone (stages 2b/3)
- **DRUG:** Anakinra and Ruxolitinib (overcome stage 3)
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT04366232
- **Lead sponsor:** Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-19
- **Primary completion:** 2020-10-02
- **Final completion:** 2020-10-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** investigator decision
- **Last updated:** 2020-12-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04366232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04366232, "Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04366232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*